Key Updates
Rigetti Computing has declined 9.97% to $20.68 since the June 5th report, marking a sharp 14.40% single-day drop that accelerated the stock's correction from post-funding highs. The catalyst for this selloff was Quantinuum's disappointing IPO debut on June 5th, which priced at $60 per share ($1.68 billion raised at a $15.6 billion valuation) but closed essentially flat despite opening at $68. This muted performance from quantum computing's largest IPO contrasts sharply with AI chipmaker Cerebras's 70% opening-day pop in May, signaling growing investor caution toward deep-tech quantum stocks despite sector-wide government support. The stock has now declined 26.43% over six months and 6.64% year-to-date, with the recent selloff breaking below the $22-23 consolidation range established in late May.
Current Trend
RGTI is in a clear downtrend following the breakdown from its $22-23 support zone. The stock has declined 19.03% over the past five days, accelerating from the gradual consolidation observed in previous reports. Year-to-date performance stands at -6.64%, with the stock trading 26.43% below its six-month high. The current price of $20.68 represents a critical juncture, testing psychological support at the $20 level. The stock has established a pattern of lower highs since the May 21st government funding announcement peak, with resistance now firmly established at $24-26. Trading volume during the recent decline suggests institutional profit-taking rather than panic selling, as the sector reassesses valuations following Quantinuum's tepid reception.
Investment Thesis
The investment thesis for Rigetti centers on its position as a government-backed quantum computing pure-play receiving $100 million in federal funding with equity participation from the U.S. Commerce Department. The company benefits from strategic validation through the Trump administration's $2 billion quantum initiative, positioning it within a diversified portfolio of nine companies deemed critical to domestic quantum chip supply chain development. However, the thesis faces headwinds from Quantinuum's significantly larger scale and valuation, which at $15.6 billion post-IPO dwarfs Rigetti's market capitalization and highlights the competitive intensity within the sector. The thesis requires Rigetti to demonstrate execution on its $100 million government contract while navigating a market increasingly differentiated between full-stack leaders like Quantinuum and specialized players.
Thesis Status
The investment thesis has deteriorated materially. Quantinuum's flat IPO debut represents a watershed moment for quantum computing valuations, signaling that investor enthusiasm has limits even for well-capitalized, Honeywell-backed companies with established revenue streams ($30.9 million in 2025). Quantinuum's Q1 2026 revenue of $5.24 million against a $128.2 million net loss demonstrates the sector's ongoing cash burn despite government support. The 20x oversubscription for Quantinuum's IPO followed by flat trading suggests institutional investors are taking profits in the broader quantum sector, which directly impacts smaller-cap names like Rigetti. The government funding remains a critical thesis pillar, but the market is now demanding clearer paths to commercialization and profitability rather than rewarding pure-play exposure. The $100 million grant provides runway but does not differentiate Rigetti from D-Wave and Infleqtion, which received identical allocations.
Key Drivers
The primary near-term driver is sector-wide sentiment following Quantinuum's disappointing market reception, which has reset valuation expectations across quantum computing stocks. The $15.6 billion valuation achieved by Quantinuum establishes a new benchmark that highlights the valuation gap between full-stack providers with commercial traction and earlier-stage companies. The $2 billion federal quantum initiative remains supportive but has been fully priced into the sector since the May 21st announcement, with the market now focused on execution milestones. IBM's $1 billion allocation for its Anderon quantum wafer foundry creates potential partnership opportunities but also intensifies competitive pressure. The upcoming deployment timeline for Rigetti's $100 million government contract will be critical, as investors seek tangible progress beyond funding announcements. Broader market conditions for deep-tech IPOs have cooled, reducing the probability of near-term liquidity events or acquisition premiums.
Technical Analysis
RGTI has broken decisively below the $22-23 support zone that held through late May, with the current $20.68 price testing critical psychological support at $20. The 14.40% single-day decline on June 5th occurred on elevated volume, indicating institutional distribution rather than retail panic. The stock has established a clear pattern of lower highs at $26.59 (May 28th), $24.09 (June 4th), and $22.97 (June 5th), confirming downtrend momentum. The five-day decline of 19.03% has pushed the stock into oversold territory on short-term momentum indicators, though the six-month decline of 26.43% suggests sustained selling pressure. Immediate resistance sits at $22-23, with stronger resistance at $24-26. A break below $20 would likely trigger additional technical selling toward the $18 level. The stock requires stabilization above $21 and reclamation of $23 to invalidate the current bearish structure.
Bull Case
- $100 million federal grant with government equity stake provides multi-year funding runway and strategic validation as one of nine companies selected for domestic quantum chip supply chain development, reducing near-term capital raising pressure and aligning Rigetti with national security priorities.
- Diversified government investment approach across nine companies reflects long-term sector development strategy rather than winner-take-all dynamics, supporting multiple quantum computing approaches and potentially benefiting specialized players like Rigetti alongside full-stack providers.
- Current 26.43% six-month decline and 19.03% five-day selloff has created valuation compression relative to government funding received, with the $100 million allocation representing significant value relative to current market capitalization and providing potential mean reversion opportunity.
- Quantinuum's flat IPO performance may reduce near-term competitive pressure for capital and talent acquisition, as the sector reset could slow aggressive expansion plans from better-capitalized competitors and allow Rigetti to execute its government contract with reduced market expectations.
- Quantum computing industry projected to generate up to $850 billion in economic value by 2040 provides long-term secular growth tailwind, with government-backed companies positioned to capture disproportionate share of early commercial applications in chemistry, machine learning, cybersecurity, and finance.
Bear Case
- Quantinuum's disappointing IPO debut despite $1.68 billion raise and 20x oversubscription signals fundamental investor caution toward quantum computing valuations, with the flat trading performance from a Honeywell-backed, revenue-generating company suggesting limited appetite for earlier-stage pure-plays like Rigetti.
- Quantinuum's $15.6 billion valuation with $30.9 million in 2025 revenue and established pharmaceutical and financial services clients demonstrates the scale disadvantage facing Rigetti, which lacks comparable commercial traction or revenue base despite receiving identical $100 million government funding.
- Quantinuum's Q1 2026 net loss of $128.2 million on $5.24 million revenue illustrates the sector's persistent cash burn despite government support, raising questions about Rigetti's ability to achieve sustainable operations with its smaller funding base and highlighting extended timeline to profitability.
- IBM's $1 billion allocation for Anderon quantum wafer foundry represents 10x Rigetti's funding and establishes formidable competitive barrier in quantum chip manufacturing, with IBM's established semiconductor expertise and customer relationships creating structural advantages in commercialization.
- Technical breakdown below $22-23 support with 19.03% five-day decline and 26.43% six-month decline indicates sustained institutional selling pressure, with the stock establishing pattern of lower highs and lower lows that typically requires significant fundamental catalyst to reverse beyond government funding already announced.